CYTK – cytokinetics, incorporated (US:NASDAQ)
Stock Stats
News
Cytokinetics (CYTK) is now covered by Wells Fargo & Company. They set an "overweight" rating and a $95.00 price target on the stock.
Cytokinetics (CYTK) was upgraded by Barclays PLC to "strong-buy".
Cytokinetics to Participate in the 25th Annual Needham Virtual Healthcare Conference
Cytokinetics (CYTK) had its price target raised by Barclays PLC from $87.00 to $95.00. They now have an "overweight" rating on the stock.
Cytokinetics MYQORZO Approval And CEO Sale Put Valuation In Focus [Yahoo! Finance]
Form DEF 14A CYTOKINETICS INC For: May 27
Form ARS CYTOKINETICS INC For: Dec 31
Form 4 CYTOKINETICS INC For: Apr 15 Filed by: Wysenski Nancy
Form 4 CYTOKINETICS INC For: Apr 15 Filed by: WIERENGA WENDELL
Form 4 CYTOKINETICS INC For: Apr 15 Filed by: Kaye Edward M. MD
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.